Stem Pharm operates in the biotechnology sector, focusing on innovative drug discovery and development. The company specializes in creating chemically defined hydrogels and pre-coated cell culture plates, which improve outcomes for cell-based applications. Stem Pharm's core offerings include neurologic disease modeling, target discovery, phenotypic drug screening, and neurotoxicity assessments. The company also provides physiologically relevant human neural organoids featuring microglia for neuroimmune drug discovery. Stem Pharm serves pharmaceutical companies, research institutions, and biotech firms looking to advance their drug discovery programs. The business model revolves around providing specialized research services and proprietary products that enhance the drug discovery process. Revenue is generated through service contracts, product sales, and collaborative partnerships.

Keywords: drug discovery, hydrogels, cell culture, neurologic disease, phenotypic screening, neurotoxicity, neural organoids, microglia, biotechnology, research services.